Objective-Factor XI (FXI) contributes to thrombotic disease while playing a limited role in normal hemostasis. We generated a unique, humanized anti-FXI antibody, AB023, which blocks factor XIIa-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa. We sought to confirm the antithrombotic activity of AB023 in a baboon thrombosis model and to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult subjects. Approach and Results-In a primate model of acute vascular graft thrombosis, AB023 reduced platelet and fibrin accumulation within the grafts by >75%. To evaluate the safety of AB023, we performed a first-in-human study in healthy adult volunteers without any serious adverse events. Overall, 10 of 21 (48%) subjects experienced 20 treatment-emergent adverse events, with 7 of 16 (44%) subjects following active treatment and 3 of 5 (60%) subjects following placebo. AB023 did not increase bleeding or prothrombin times. Anticoagulation was verified by a saturable ≈2-fold prolongation of the partial thromboplastin time for over 1 month after the highest dose. Conclusions-AB023, which inhibits contact activation-initiated blood coagulation in vitro and experimental thrombus formation in primates, produced a dose-dependent duration of limited anticoagulation without drug-related adverse effects in a phase 1 trial. 
C ardiovascular disease and venous thromboembolism (VTE) remain leading causes of death in the United
States and other developed countries. 1 Primary prevention, acute treatment, and secondary preventative strategies for cardiovascular disease and VTE such as anticoagulation and antiplatelet therapy are effective, but universally increase the risk of bleeding. With the widespread adoption of the direct oral anticoagulants for a large majority of VTE indications over the last several years, bleeding rates have been reduced, though not abolished; indeed, annual major bleeding rates with direct oral anticoagulants are reported to be 4%, with mortality rates reaching 25% after intracranial hemorrhage. 2 In addition, breakthrough thrombosis remains problematic with direct oral anticoagulants as well as other forms of anticoagulation, and many clinical scenarios such as intravascular devices (eg, hemodialysis, mechanical cardiac valves, and ventricular assist devices) remain areas of critically unmet medical need. For example, device failure (16.2%) and stroke (29.7%) are common events with ventricular assist devices despite anticoagulation with a vitamin K antagonist. 3 In other settings such as sepsis, novel forms of anticoagulation, although initially promising, failed to show a convincing benefit in phase 3 trials. 4, 5 
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Given the numerous clinical indications for anticoagulation, development of novel anticoagulants with the potential to outperform the current therapeutic standard has become a high research priority. Previously ignored by modern anticoagulation strategies, the contact activation system, including the intrinsic pathway of thrombin generation, has garnered increasing attention. Mounting preclinical and clinical evidence supports the role of contact factors XI (FXI) and XII (FXII) in promoting pathological thrombosis and inflammation, and establishes these enzymes as promising targets for the development of drugs with both anticoagulant and anti-inflammatory properties, with the distinct potential benefit of leaving bleeding risk unaffected. Congenital FXII deficiency, for instance, appears to have no associated phenotypic bleeding diathesis; congenital FXI deficiency (hemophilia C) confers a mild bleeding risk that generally manifests only in the face of significant hemostatic challenge. 6 Epidemiological data suggest that individuals deficient in FXI are also significantly protected against venous and arterial thromboembolic diseases. 7, 8 This association was later corroborated by the results of a prospective clinical trial using a FXI antisense oligonucleotide which showed that reducing FXI levels provided superior prophylaxis against surgically-provoked VTE, as well as a lower incidence of bleeding when compared with traditional anticoagulation. 9 Our group developed a novel murine IgG2b monoclonal antibody (14E11) targeting the apple 2 domain of FXI. This antibody inhibits the activation of FXI by activated FXII (FXIIa) as well as inhibiting reciprocal FXII activation by FXIa, without inhibiting the activation of FIX by FXIa or hemostatic FXI activation by thrombin. 10 The antithrombotic and anti-inflammatory effects of 14E11, administered intravenously or subcutaneously, were demonstrated in multiple in vivo models including device-associated thrombosis, arterial thrombosis, and polymicrobial or listeria sepsis. [10] [11] [12] [13] [14] This work culminated in the development of AB023 (also referred to elsewhere as xisomab 3G3, or 3G3), a recombinant, humanized anti-FXI apple 2 domain antibody with ≈70% homology to the 14E11 antibody, which we evaluated in preclinical safety and efficacy studies as well as the herein described phase 1 clinical trial. The aims of this first-in-human, dose-escalation study were to describe the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single ascending, intravenous bolus dose of AB023 in healthy volunteers as compared with placebo.
Methods
Because of the sensitive nature of the data collected for this study, requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to the corresponding author at Aronora, Inc.
The AB023 phase 1 clinical study was preregistered before conducting research.
Please see the Major Resources Table in the online-only Data Supplement.
AB023 Humanization and Manufacturing Cell Line Development
The antibody AB023 was generated by complementarity determining region-grafting technology at Antitope, Ltd (Cambridge, United Kingdom). The variable region genes from the monoclonal mouse anti-human FXI antibody 14E11 were sequenced to design a series of humanized antibody variants. Humanized variable region genes were designed based on human germline sequences with the closest homology to the murine sequences and constructed by gene synthesis. These were then cloned into separate vectors containing human IgG 4 genes. The humanized antibody was stably expressed and tested for binding to human FXI by competition enzyme-linked immunosorbent assay (ELISA) against biotinylated 14E11. The lead candidate antibody was chosen based on the competition binding ELISA and activity in the in vitro activated partial thromboplastin (aPTT) assay, and a stable manufacturing cell line was generated at Antitope, Ltd (Cambridge, United Kingdom) using Composite CHO™ Technology.
AB023 Manufacturing
The antibody AB023 was manufactured at Bayer Healthcare LLC, Berkeley, CA. Briefly, the cells used to inoculate the production bioreactor originated from the AB023 master cell bank. Cells were cultured using a fed-batch process and harvested at 14 days. Purification consisted of 3 chromatography column steps, 2 specific viral clearance steps, followed by concentration and diafiltration. After final formulation in a buffer containing histidine, arginine-HCl, methionine, sucrose, and polysorbate 80, the AB023 was filtered into the drug substance containers and stored frozen until fill/finishing as a lyophilized drug product (15 mg/mL after reconstitution).
Binding Affinity for FXI and FXIa
The antibody AB023 was biotinylated using the EZ-Link TM Sulfo-NHS-Biotinylation Kit (Thermo Scientific) as per instructions. FXI or FXIa (2 µg/mL, 100 µL/well) in 50 mmol/L Na 2 CO 3 pH 9.6 was incubated overnight at 4°C in Immulon 2HB microtiter plates (Thermo Scientific). Wells were blocked with 150 µL phosphate buffered saline (PBS) with 2% BSA for 1 hour at room temperature. One hundred microliters biotinylated AB023 (0.7 pmol/L-6.7 µmol/L) in 90 mmol/L HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) pH 7.2, 100 mmol/L NaCl, 0.1% BSA, 0.1% Tween-20 (HBS [HEPES-buffered saline]) was added, and incubated for 90 minutes at room temperature. After washing with PBS-0.1% Tween-20 (PBS-T), 100 µL streptavidin-horse-radish peroxidase (Thermo Scientific, 1:8000 dilution in HBS) was added, with incubation at room temperature for 90 minutes. After washing with PBS-T, 100 µL substrate solution (12 mL 30 mmol/L citric acid; 100 mmol/L Na 2 HPO 4 , pH 5.0; and 1 o-phenylenediamine dihydrochloride tablet, 12 µL 30% H 2 O 2 ) was added. Reactions were stopped after 10 minutes with 50 µL 2. 
Western Blotting
Biotinylated AB023 (10 µg/mL) was the primary antibody in Western blots of recombinant FXI with individual apple domains replaced with corresponding domains from human PK (prekallikrein), or individual FXI apple domains attached to recombinant tPA (tissue-type plasminogen activator) as previously described. 10 Detection was performed with streptavidin-horse-radish peroxidase and chemiluminescence.
In Vitro Activation of FXI by FXIIa
FXI (30 nmol/L) was incubated with 0.5 nmol/L α-FXIIa and dextran sulfate (0.1 µg/mL) at 37°C in 25 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, and 0.1% BSA in the presence or absence of AB023 (0 nmol/L to 300 nmol/L). After 30 minutes of incubation, samples were removed and quenched with polybrene (6 µg/mL) to neutralize dextran sulfate and CTI (corn trypsin inhibitor; 50 µg/mL) to inactivate FXIIa, after which the generation of FXIa was quantified by measuring rates of S-2366 hydrolysis at 405 nm. Rates of S-2366 hydrolysis were converted to FXIa concentrations using a standard curve.
In Vitro Activation of FXI by Thrombin
FXI (30 nmol/L) was incubated with 2.5 nmol/L α-thrombin and dextran sulfate (0.1 µg/mL) at 37°C in 25 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, and 0.1% BSA in the presence or absence of AB023 (300 nmol/L). After 0, 5, 15, 30, or 60 minutes incubation, the samples were removed and quenched with polybrene (6 µg/mL) to neutralize dextran sulfate and hirudin (10 U/mL) to inactivate thrombin, after which the generation of FXIa was quantified by measuring rates of S-2366 hydrolysis at 405 nm. Rates of S-2366 hydrolysis were converted to FXIa concentrations using a standard curve.
Coagulation Assays

Activated Partial Thromboplastin Time Assay
Pooled plasmas from human, baboon, rat, or cynomolgus monkey (90 µL, from 3 individual subjects) anticoagulated with 0.38% sodium citrate were mixed with 10 µL of AB023 (0.183-1500 µg/mL) or control (PBS) and allowed to incubate at room temperature for 5 minutes. Forty microliters of the plasma/antibody mixture were then incubated with 40 µL of aPTT reagent (SynthASil, No. 0020006800, Instrumentation Laboratory, Bedford, MA) for 3 minutes at 37°C. After incubation, 40 µL of CaCl 2 was added and time to clot was determined on a KC4™ Analyzer (Tcoag, Bray, Ireland). Each sample was assayed in duplicate. For each species tested, the aPTT data was expressed as fold change of baseline and plotted against the log 10 concentration of AB023.
Prothrombin Time Assay
Prothrombin time (PT) of plasma samples was measured using Dade Innovin (Siemens Healthcare Diagnostics, Berlin, Germany), reconstituted according to the manufacturer's recommendation before sample measurement. To measure PT, 40 µL of 0.32% sodium citrate anticoagulated plasma collected from baboons was incubated at 37°C for 3 minutes, and 80 µL of PT reagent was added. Samples were measured in duplicate using a KC4 coagulometer.
Baboon Vascular Graft Thrombosis Model
All animal experiments were approved by the Institutional Animal Care and Use Committee of Oregon Health & Science University. A total of 8 nonterminal experiments were performed using 4 juvenile male baboons (Papio anubis) with a surgically placed, healed, chronic exteriorized arterio-venous shunt connecting the femoral artery and vein, as described previously. 15 Briefly, a collagen-coated 20 mm long, 4 mm internal diameter vascular graft segment was deployed into the arterio-venous shunt of the baboon for the duration of 90-minute-long acute thrombosis experiments. Only male animals were used in these studies in accordance with the National Institutes of Health policy guidance NOT-OD-15-102 for single-sex studies when using acutely scarce resources, which applies to nonhuman primates because of animal safety concerns. To protect the chronicallyimplanted shunt site, the animals wear protective suits which prevent them from accessing the shunt site at all times. Female baboons have significant swelling of their sex organs during their menstruation cycles, which prohibits the use of secure protective suits. Without these suits, a catastrophic failure is imminent as the animal is then able to physically remove the shunt. Every effort (including suit redesign and birth control to reduce swelling) has been made to attempt to alleviate this risk. Unfortunately, none are able to significantly protect the female animals and, therefore, only male animals were used.
Thrombus formation in the graft during perfusion was assessed by dynamic quantitative gamma camera imaging of radio-labeled autologous platelet content in the graft segment, and further assessed by measurement of retained fibrin content within the graft after termination of each experiment, as previously described in detail. 15 Briefly, platelet-associated 111 In radioactivity within the grafts was determined at 5-minute intervals using a GE-400A-61 gamma scintillation camera. Since graft thrombi formation propagate and extend distally (downstream) from the graft over time, platelet accumulation was also measured within a 10 cm long region immediately distal to the graft. The real-time radio imaging of platelets thus monitors thrombus growth within the thrombogenic graft (thrombus head), as well as the thrombus that propagates distally to the collagen segment (thrombus tail). Homologous 125 I-labeled baboon fibrinogen incorporation into the thrombus was assessed by measuring the radioactivity using a gamma counter (Wizard-3, PerkinElmer, Shelton, CT).
First-in-Human Trial Design
We performed a phase 1, randomized, double-blind, placebo-controlled, single ascending bolus dose study at a single site (Celerion, Tempe, AZ) in healthy adult volunteers to test the safety, tolerability, pharmacokinetics, and pharmacodynamics of AB023. This clinical trial was approved by the Chesapeake Institutional Review Board before initiation as required by and conducted in accordance with the Declaration of Helsinki, International Council for Harmonization, and Good Clinical Practice. Written informed consent was obtained from all participants before enrollment in the trial.
The study consisted of 4 ascending dose cohorts (0.1, 0.5, 2.0, and 5.0 mg/kg). In each cohort, subjects were randomized to receive a single intravenous bolus injection of AB023 (n=4 per cohort) or placebo (n=1 per cohort, except for the 0.1 mg/kg dosing cohort in which n=2; Figure 1 ). Both investigators and subjects were blinded to treatment. A data safety monitoring committee that was blinded to treatment provided oversight of this phase 1.
Eligibility Criteria
This study included healthy adults 18 to 48 years of age with a body mass index ≥19 and ≤29.0 kg/m 2 and weight between 50 and 125 kg with normal hepatic and renal function. Subjects were required to have aPTT, PT, the international normalized ratio, and platelets within the limits of normal range at enrollment along with a bleeding time (BT) between 2 and 8 minutes. Only women of nonchildbearing potential were eligible for the trial, and all fertile males were required to use an approved form of birth control throughout the duration of the study.
Endpoints
The primary endpoint of the study was the number and severity of treatment-emergent adverse events (TEAEs) following single doses of AB023 or placebo. The patients were observed for adverse events (AEs), and blood samples were repeatedly drawn for laboratory analyses. Other safety parameters included PT, (BT, Surgicutt®), clinical laboratory values, vital signs, and drug immunogenicity. Immunogenicity was evaluated from study plasma samples that were pretreated to remove endogenous FXI and an acid dissociation step to reduce interference. The samples were then assayed for anti-drug antibodies using a sandwich ELISA procedure using AB023 to capture anti-drug antibodies and biotinylated AB023 and streptavidinhorse-radish peroxidase for detection. Secondary endpoints included drug pharmacokinetics and pharmacodynamics, the latter represented by aPTT values.
Pharmacokinetics and Pharmacodynamics
For all subjects, blood samples for pharmacokinetics and pharmacodynamics assessment were collected at predose, and at 0.083, 0.25, 0.5, 1, 3, 8, 24, 72, 120, 168, 216, 336, 504, and 672 hours after the start of AB023 or placebo administration. Following the 672-hour time point, sample collections for pharmacokinetic assessments continued every 7 days (±2 days) until aPTT values returned to the normal range or within ±10% of the baseline. Free plasma AB023 concentrations were determined using a validated ELISA method. Pharmacokinetic endpoints included total exposure (AUC 0-inf ), exposure up to last measurable concentration (AUC 0-t ), the percent of the AUC 0-inf that was extrapolated (AUC %extrap ), elimination rate constant (K el ), maximum plasma concentration (C max ), clearance (CL), half-life of elimination (T 1/2 ), mean absorption time, and volume of distribution (V ss ) at steady state. APTT was used as a pharmacodynamic biomarker.
Statistics
All statistics were calculated using R (R foundation for statistical computing, Vienna, Austria, version 3.5.1) unless otherwise noted. For all tests reported here, statistical significance is defined as P<0.05. The assumptions underlying parametric tests were checked by confirming the normal distributions of model residuals using quantile-quantile plots. Equal variance assumptions were confirmed using Levene's test.
Baboon vascular graft thrombosis model: Numeric values are shown as mean and range in the text, while mean±SEM are shown in the figures. Means of fibrin deposition were compared by MannWhitney U test for treatment versus control. Comparisons between Figure 1 . Dose escalation schedule for the AB023 first-in-human phase 1 clinical trial. Each cohort was dosed sequentially. Once subjects were screened and met eligibility criteria, they were randomized to receive either AB023 or placebo at a 4:1 ratio, except for cohort 1 where the AB023: placebo ratio was 4:2 to accommodate 2 sentinel subjects (1 active and 1 placebo). Before dose escalation to the next dose, all safety data was collected from each subject through day 28 and reviewed by a safety review committee during a dose escalation safety review meeting. AB023 and control treatment results of platelet deposition rates over time were performed by a linear mixed effects model with main effects calculated for treatment, time and interaction, and random effects calculated for trial (package nlme version 3.1-137). Because the treatment variable had only 2 levels, post-hot tests were not performed.
Phase 1 Clinical Trial
The study sample size was chosen to enable appropriate safety and tolerability assessment while ensuring that a minimal number of healthy participants were exposed to the investigational drug. Descriptive statistics were used to evaluate safety endpoints. The appropriate noncompartmental pharmacokinetic parameters were calculated from the plasma AB023 concentration-time data using Phoenix® WinNonlin®, Version 7.0. Actual sample times were used in the calculations of the pharmacokinetic parameters. The calculation of the actual time for AB023 was in respect to the start of infusion time of AB023 on Day 1. The plasma concentrations of AB023 are shown as mean±SEM concentration-time profiles are presented on a linear scale. Pharmacokinetic concentrations and pharmacokinetic parameter descriptive statistics were generated using SAS, Version 9.3 (SAS Institute, Cary, NC). Mean±SEM aPTT and PT value-time profiles and change are presented on a linear scale. Bleeding time data were analyzed with a 1-way ANOVA with treatment as a categorical variable whereas PT data were analyzed with a 2-way repeated measures ANOVA against dosage and sample time. Bleeding time and PT data were analyzed with post hoc Dunnett tests as appropriate.
Results
Humanized Anti-FXI Antibody AB023 Inhibits FXIIa Activation of FXI
The recombinant humanized antibody, AB023, binds to the apple 2 domain of FXI and FXIa with high affinity (K d =3.66 and 1.38 nmol/L respectively, 16 Figure 2A through 2C) and inhibits activation of FXI by FXIIa in a concentration-dependent manner ( Figure 2D ) but does not inhibit thrombin-mediated activation of FXI ( Figure 2E ). AB023 prolonged the aPTT of plasma from normal rats, baboons, cynomolgus monkeys, and humans in a concentration-dependent manner ( Figure 2F ) by about 2-fold at and above saturating concentrations, which was similar to the anticoagulant effect of the murine antibody, 14E11.
AB023 Is Antithrombotic in a Baboon Model of Thrombosis
The antithrombotic effects of AB023 were characterized in a well-established vascular thrombosis model performed as previously described. 15, [17] [18] [19] A single 1.0 mg/kg intravenous injection of AB023 reduced platelet accumulation within collagen-coated vascular grafts ( Figure 3A) , and near complete inhibition of platelet accumulation was achieved in the region 10 cm immediately downstream of the graft (the tail; Figure 3B ) comparedwith vehicle control. Overall, total platelet accumulation (platelet accumulation within the thrombogenic graft plus the tail) was significantly reduced after pretreatment with 1.0 mg/kg AB023 ( Figure 3C ). Total fibrin deposition (graft+tail) was decreased after AB023 treatment ( Figure 3D through 3F ). These studies indicate that AB023, like its murine precursor, is antithrombotic in a primate acute vascular graft thrombosis model. APTT was prolonged following AB023 treatment at 30 and 60 minutes after injection (Table 1 ) and remained elevated beyond 24-hour post-treatment (data not shown). No change in aPTT was observed in the control group. PT was also measured before AB023 treatment, as well as 60 minutes and 24 hours after treatment; treatment with AB023 did not alter the PT compared with controls (Table 1) .
First-in-Human Study
A total of 21 subjects entered the study, received the study medication, completed the study per protocol, and were Table 2 .
Safety
There were no serious AEs experienced in this study. No subjects were removed from the study because of AEs. Overall, 10 of 21 (48%) subjects experienced a total of 20 TEAEs in this study, with 7 of 16 (44%) subjects following active treatment and 3 of 5 (60%) subjects following placebo (Table 3) . Three (19%) active-treatment subjects experienced 5 events that were suspected to be possibly treatment-related by the principal investigator (PI). The most common TEAE in this study was a productive cough, considered unrelated or unlikely treatment-related, experienced by 2 (13%) active-treatment subjects, with 1 subject receiving 0.5 mg/kg AB023 and 1 subject receiving 5.0 mg/kg AB023. One event of a productive cough was mild (Grade 1) in severity (0.5 mg/kg AB023), and the other (5.0 mg/kg AB023) was moderate (Grade 2). Onset for these events was 35 days and 50 days post-dose, with resolution at 1 hour and 9.5 days, respectively. All other TEAEs were experienced by 1 subject each. The majority of events (17) were mild (Grade 1) in severity and 3 were moderate (Grade 2). Of these AEs, the principal investigator considered the following to be possibly treatment-related (treatment in parenthesis): increased diastolic blood pressure (2.0 mg/kg AB023) which resolved spontaneously after 4.5 hours, injection site ecchymosis on the inside of the left upper arm after several failed attempts to inject in the antecubital vein (0.5 mg/kg AB023), 2 events of injection site pain (0.5 mg/kg AB023), and generalized pruritus (0.5 mg/kg AB023). AB023 had no effect on mean BT or PT in any study subject in any of the examined cohorts ( Figure 4A and 4B) . Three subjects received acetaminophen during the study for resolution of events considered unrelated or unlikely treatment related. Two subjects received nondrug therapy for resolution of events considered unrelated or unlikely treatment-related. Finally, anti-drug antibodies were not detected in the plasma of any subjects. Overall, AB023 was found to be safe and well-tolerated in healthy human volunteers.
Pharmacokinetics
Plasma AB023 was detectable in all subjects at the time of first sampling (0.08 hour post start of infusion). Plasma AB023 remained detectable in the majority of subjects up to 0.5 hour and 120-hour post-dose for the 0.1 and 0.5 mg/ kg dose levels, respectively. Plasma AB023 remained detectable in all subjects throughout the entire sampling interval (672 hours) for the 2.0 mg/kg and 5.0 mg/kg dose levels. Mean peak plasma concentrations of AB023 occurred at ≈0.08 hours for the 0.1 mg/kg and 2.0 mg/kg dose levels, 0.25 hours for the 0.5 mg/kg dose level, and 1 hour for the 5 mg/kg dose level. Ascending doses of AB023 increased the peak and overall AB023 exposure in a slightly more than a dose-proportional manner from the 0.5 mg/kg to 5.0 mg/kg dose levels ( Figure 5) .
Following administration of a single intravenous injection of AB023, plasma exposure (AUCs and C max ) increased with increasing AB023 doses. Geometric mean AUC 0-t , AUC 0-inf , and C max values ranged from 57 to 28×10 6 ng·h/mL, 185 to 28×10 6 ng·h/mL, and 123 to 1.3×10 5 ng/mL, respectively, after administration of 0.1 mg/kg to 5.0 mg/kg dose. Median T max values varied between 0.08 hour to 0.65 hour post-dose. Arithmetic mean T 1/2 values appeared to increase with increasing AB023 doses and ranged from ≈1.3 hours following the 0.1 mg/kg AB023 dose to ≈121.5 hours following the 5.0 mg/kg dose. Total plasma clearance (CL) was ≈37.5 L/h, and volume of distribution (V ss ) was ≈69.1 L for the 0.1 mg/kg dose (n=1 for both values), representing the underestimation of exposure at this dose level. Arithmetic mean CL appeared to decrease with increasing AB023 doses and ranged from ≈0.094 L/h to 0.014 L/h following the 0.5 mg/kg to 5.0 mg/ kg dose. V ss appeared to increase with increasing AB023 dose, ranging from ≈2.5 L for the lowest to 4.3 L for the highest dose (Table 4) .
Pharmacodynamics
Individual predose aPTT values ranged from 23 to 32 seconds in all subjects. Administration of AB023 produced an expected prolongation of aPTT in all subjects receiving the active compound ( Figure 4C and 4D) . Overall, the mean aPTT values reached a maximum aPTT prolongation at ≥0.5 mg/kg. This saturating effect was expected from AB023 as a result of binding all free FXI and reflects the understood mechanism of action of AB023. Mean aPTT values were highest or close to/within the error margins of maximum between 0.25 and 24 hours post-dose at all concentrations tested (from 0.1-5.0 mg/ kg). The aPTT values decreased with time whereby the lowest dose level (0.1 mg/kg) decreased faster than the highest dose level (5.0 mg/kg). The aPTT values returned to baseline (±10%) by 24 hours and 336 hours for all subjects at dose levels 0.1 mg/kg and 0.5 mg/kg, respectively. Most subjects in dose levels 2.0 mg/kg and all subjects in dose level 5.0 mg/ kg returned to baseline past the last planned time point at 672 hours ( Figure 4C ).
Discussion
Although currently available anticoagulants are effective at preventing thrombosis, all existing therapies can significantly increase bleeding risks, leading to substantial morbidity, elevated health care costs, and in some cases resulting in death. Consequently, safer anticoagulants that do not impair hemostasis are a critical unmet need. Recent clinical studies implicate the blood coagulation contact system as a promising target for safer anticoagulation. 9 We have developed a novel, recombinant antibody, AB023, that binds the FXI apple 2 domain and selectively inhibits FXI activation by FXIIa, inhibits the activation of FXII by FXIa, as well as inhibits contactassociated FXI autoactivation in vitro. 12 Importantly, our in vitro data also demonstrate that AB023, like its murine precursor 14E11, does not prevent FXI activation by thrombin. 10 These observed substrate specific alterations conferred upon FXI/FXIa upon binding to AB023, and the lack of AB023 effect on FXI activation by thrombin suggest a hypothetical mechanistic rationale for AB023 to not increase the iatrogenic bleeding risk that may be seen with more direct FXI/FXIa inhibition or antagonism.
Although lowering FXI levels using antisense oligonucleotides was associated with less orthopedic surgery-related bleeding events than traditional heparin anticoagulation clinically, 9 an abundance of epidemiological data still suggests a mild yet variable bleeding phenotype associated with FXI deficiency. 6 By preserving the proteolytic functions of the FXI active site, as well as the ability of thrombin to activate FXI, AB023 selectively halts the coagulation cascade when initiated by contact activation, essentially rendering AB023 as a functional FXIIa inhibitor within the classical cascade model of blood coagulation. Patients deficient in FXII, although rare, have not been described as having any abnormal bleeding phenotype, further supporting the notion that the pathway AB023 inhibits may be completely dispensable for hemostasis. In vivo, experimental thrombosis studies using the murine precursor 14E11 corroborate this hypothesis, with no unusual bleeding events nor changes in prothrombin or bleeding times detected. 10, 11 Lastly, no bleeding side effects were observed in either of the pivotal GLP toxicity studies performed using supratherapeutic doses of AB023 in rats and cynomolgus monkeys (data not shown). These studies, along with the data presented here, demonstrate the potent antithrombotic efficacy and hemostatic safety of AB023 in experimental models and strengthen the hypothesis that FXIIa-dependent FXI activation, while inconsequential for hemostasis, appears to be pathological in certain settings.
Novel agents that completely abrogate FXI function, such as antisense oligonucleotides that inhibit the production of FXI or antibodies that inhibit the hemostatic functions of FXI/ FXIa, are more likely to result in a bleeding phenotype similar to individuals with hemophilia C. 9, 20 Although bleeding in these cases is mild and typically only provoked by substantial hemostatic challenges medical support and anticoagulation reversal may be required in dire circumstances. As it pertains to hemostatic capacity, we propose that individuals who receive AB023 are likely to behave in a clinically similar fashion to individuals born deficient in FXII. Such individuals have no known bleeding or other pathological phenotype and can undergo major surgery without any specific interventions. 21 Therefore, bleeding that occurs in patients exposed to AB023 can likely be managed similarly to patients with an intact coagulation system. The phase 1 trial described here is the first to evaluate the safety of AB023 in humans. Most notably, no high-grade AEs occurred in patients who received AB023 at any of the escalating doses from 0.1 mg/kg to 5.0 mg/kg, suggesting the drug is safe and well tolerated. A single grade 1 injection site ecchymosis event was observed in an AB023 treated subject (0.5 mg/kg) after several failed attempts to inject in the antecubital vein resulted in an unconventional injection site on the upper arm. The most common AE (cough) was unlikely related to the drug. Finally, although AB023 prolonged aPTT in a dosedependent manner, PT or BT were not detectably altered.
The pharmacokinetic parameters of AB023 obtained from this study revealed that escalating doses of AB023 predictably increased plasma drug exposure (AUCs and C max ). Interestingly, T 1/2 increased with increasing doses of the drug and, conversely, CL decreased with increasing doses. This phenomenon can likely be explained by both the use of an ELISA method that detected only free AB023, and target-mediated drug disposition, where a proportion of drug administered is bound with high affinity to plasma FXI, which is reflected in the pharmacokinetic properties of the drug. 22, 23 These effects on apparent pharmacokinetic parameters such as T 1/2 , V ss , and CL are often dose-dependent, as was observed for AB023 in this study. Indeed, we found that the terminal elimination phase was better characterized at the highest AB023 doses, where plasma concentrations of antibody were far above target saturation. At these high antibody concentrations, relative to FXI, elimination is likely approaching a first-order process where the FcRn (neonatal FC receptor)-mediated pathway is dominant, and target-mediated drug disposition is less of a factor. Target-mediated drug disposition is also likely responsible for the V ss that was lower than the physiological blood volume. V ss was likely only characterized appropriately at the highest dose level where V ss approached the physiological blood volume. The use of an ELISA method that detects only free antibody is a clear limitation to the study and does not reveal the full scope of AB023 pharmacokinetics. To address this, an ELISA method to detect total AB023 is under development, and banked plasma samples will be evaluated once this assay is validated and available. We also found a predictable, dose-dependent response in aPTT after AB023 administration, with a 5.0 mg/kg dose measurably prolonging aPTT for over 4 weeks. This finding holds promise for patient populations that require anticoagulation for both subacute and chronic indications, including postoperative VTE prophylaxis (current guidelines mandate weeks of postoperative anticoagulation for certain scenarios 24 ), mechanical heart valves (a population in which direct oral anticoagulants are inferior to alternatives), 25 chronic indwelling catheters, hemodialysis patients with atrial fibrillation, and bacterial sepsis with disseminated intravascular coagulation. These considerations, along with the favorable results of this phase 1 trial, have led to our currently enrolling phase 2 trial evaluating the safety and preliminary efficacy of AB023 in end-stage renal disease patients receiving chronic hemodialysis http://www.clinicaltrials.gov. Unique identifier: NCT03612856) where the primary objective is to measure safety and tolerability in this patient population. Preliminary efficacy will also be evaluated as a secondary objective by visual assessment of thrombus accumulation within the dialyzer cartridge, 26 protein accumulation within the dialyzer cartridge, and improved efficiency of hemodialysis.
Although AB023 is a FXI antibody that essentially serves as a functional FXIIa inhibitor, it is distinct from antibodies in development targeting FXIIa itself. 27 While these 2 strategies have not been compared in humans, and any potential differences in safety and efficacy are speculative, several possible distinctions are worth discussing. Besides the fact that the average concentrations of circulating plasma FXII and FXI differ to a substantial degree (375 nmol/L versus 30 nmol/L, respectively) 28, 29 there is also a theoretical benefit to targeting the circulating zymogen form of FXI as opposed to the activated serine protease FXIIa; in the latter scenario, the antibody may compete with other substrates for the FXIIa catalytic domain. Lastly, AB023 may have fewer off-target effects by preserving the other in vivo functions of FXIIa, including activation of the kinin-kallikrein system.
There are limitations to the evaluation of AB023 in animals and humans that should be discussed. First, the ability of AB023 to inhibit the growth of an already existing thrombus was not evaluated in our baboon thrombosis model and, therefore, it is unknown whether AB023 would be effective as an interventional treatment for thrombosis. In addition, although our studies show that AB023 reduced contact pathway-initiated experimental thrombosis, its effectiveness in preventing thrombosis initiated by tissue factor has not yet been evaluated. However, the parent antibody 14E11 was indeed able to limit lethal pulmonary embolism induced by tissue factor injection in a mouse model. 10 Previous studies also show that total inhibition of FXI activity reduced tissue-factor induced experimental thrombus growth, 18 however, because this result could be due to FXI activation via thrombin 30 it is unknown whether AB023 would be similarly effective.
Another significant limitation of the phase 1 study is the inability to accurately assess bleeding risk with existing techniques. Although it is reassuring that no clinically significant bleeding occurred and that the PT and BT were not changed by any dose of AB023 in this study, these parameters have significant variability and are limited predictors of actual bleeding risk, for example, in hemophilia, when the values are often within the normal range. Second, as with any phase 1 trial, small sample size limits the ability to detect rare side effects which are possible with any drug. AUC 0-t indicates area under the concentration-time curve, from time 0 to the last observed nonzero concentration (t); AUC 0-inf , area under the concentration-time curve, from time 0 extrapolated to infinity; AUC %extrap , percent of AUC 0-inf extrapolated; C max , maximum plasma concentration; CL, apparent total plasma clearance; K el , apparent terminal elimination rate constant; T 1/2 , apparent terminal elimination half-life; T max , time to reach maximum observed concentration; and V ss , total apparent volume of distribution following single IV dose
In conclusion, we have shown that targeting contact activation by selective antibody-mediated inhibition of FXIIadependent FXI activation is feasible with AB023. There were no major safety concerns in this first-in-human trial, and overall, AB023 was well tolerated in healthy volunteers. We have developed a strong preclinical rationale suggesting this drug could be efficacious in a variety of common settings that might benefit from inhibiting contact activation. Indeed, targeting the blood coagulation contact pathway with drugs like AB023 has the potential to uncouple bleeding from thrombosis, which has been inexorably linked with traditional anticoagulants, and alter the way we offer antithrombotic treatments going forward.
